Table 1.
Base case | Comparator | |
---|---|---|
Treatments | Dasatinib | Nilotinib |
Expected annual cost | $64,045.02 | $58,695.35 |
Patient success (MMR/CCyR) | 0.28 | 0.55 |
CE ratio | $228,732 | $107,688 |
Incremental cost | −$5,349.67 | |
Incremental effect | 0.27 | |
ICER | −$20,183.48 |